20.500.12556/DiRROS-29845 Exploring early DNA methylation alterations in type 1 diabetes implications of glycemic control Background: Prolonged hyperglycemia causes diabetes-related micro- and macrovascular complications, which combined represent a significant burden for individuals living with diabetes. The growing scope of evidence indicates that hyperglycemia affects the development of vascular complications through DNA methylation. Methods: A genome-wide differential DNA methylation analysis was performed on pooled peripheral blood DNA samples from individuals with type 1 diabetes (T1D) with direct DNA sequencing. Strict selection criteria were used to ensure two age- and sex-matched groups with no clinical signs of chronic complications according to persistent mean glycated hemoglobin (HbA1c) values over 5 years: HbA1c<7% (N=10) and HbA1c>8% (N=10). Results: Between the two groups, 8385 differentially methylated CpG sites, annotated to 1802 genes, were identified. Genes annotated to hypomethylated CpG sites were enriched in 48 signaling pathways. Further analysis of key CpG sites revealed four specific regions, two of which were hypermethylated and two hypomethylated, associated with long non-coding RNA and processed pseudogenes. Conclusions: Prolonged hyperglycemia in individuals with T1D, who have no clinical manifestation of diabetes-related complications, is associated with multiple differentially methylated CpG sites in crucial genes and pathways known to be linked to chronic complications in T1D type 1 diabetes glycemic control DNA methylation diabetes-related complications long-read sequencing true false true Angleški jezik Ni določen Neznano 2026-06-08 12:46:44 2026-06-08 12:46:44 2026-06-09 03:49:21 0000-00-00 00:00:00 2024 0 0 Nasl. z nasl. zaslona; Opis vira z dne 13. 6. 2024; str. 1-10 Vol. 15 5 June 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 61 1664-2392 10.3389/fendo.2024.1416433 198843395 RAZ_Cugalj_Kern_Barbara_2024.pdf RAZ_Cugalj_Kern_Barbara_2024.pdf 1 563C28760D183341BB683F1C18A47FBD 4803cee3c9e9e680aa35e5739103c28c2b64acb5e66e7c2694e59d62ed82ec28 7459b0af-6327-11f1-9215-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=44895 https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1416433/full 1 58b0c342-6327-11f1-9215-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=44894 Univerzitetni klinični center Ljubljana 0 0 0